2 August 2021, KHARTOUM: The Federal Ministry of Health (FMoH), the United Nations Development Programme (UNDP), World Health Organization (WHO) and partners have commenced the roll-out of a new HIV treatment in Sudan, supported by the Global Fund. The new medication is part of WHO’s recommended treatment guidelines and will help the 46,000 people estimated to be living with HIV in Sudan. The rollout was initially planned for 2020, however to the due to the COVID-19 pandemic, it was delayed.

Following the adoption of the WHO treatment guidelines by the FMoH, the medication is being introduced at all 42 HIV treatment centres nationwide. The rollout has been accompanied by FMoH, UNDP, WHO and UNAIDS-supported training for healthcare staff, and improvements to individual patient monitoring.

On the World Health Organization's List of Essential Medicines, antiretroviral (ARV) drug ‘Dolutegravir’ is recommended as the preferred treatment for all populations, based on its effectiveness, fewer side effects, high genetic barrier for resistance and improved life expectancy of the person taking it.

Planned for nationwide deployment in phases over the next three years, the first phase expects to have 45% of current antiretroviral treatment recipients transitioned to the new medication by the end of the year.

“This is a step forward in improving the lives of those living with HIV, one we are thrilled to see happen,” said Thowiba Khougli Head of the Procurement and Supply Chain Management Unit at FMOH's Disease Control Directorate. “This transition is thanks to the ongoing support and strong relationships with our partners - the Global Fund, UNDP, WHO and others – and our thanks go to them for the assistance in delivering a life-improving outcome to some of our most vulnerable.”

In the second, planned for 2022, enrolment is expected to reach 75% of those living with HIV, growing to 90% by 2023.

In preparation for the launch, the Ministry of Health’s Disease Control Directorate in close collaboration with WHO, undertook extensive work to adapt the treatment guidelines for Sudan’s conditions, conducting dialogues with healthcare providers, national organizations, international organizations, policymakers, and people living with HIV. Utilizing Global Fund support, UNDP supported procurement of medication into Sudan, with the Ministry providing training for medical staff with technical support from UNDP, WHO, and other partners.

### ### ###

For further information, contact:

UNDP

William Seal
Head of Communications
UNDP Sudan
will.seal@undp.org
09009 21412

UNDP is the leading United Nations organization fighting to end the injustice of poverty, inequality, and climate change. Working with our broad network of experts and partners in 170 countries, we help nations to build integrated, lasting solutions for people and planet.

Learn more at undp.org or follow at @UNDP.

WHO

Hamza Ansari

External Relations Officer

WHO Sudan

aansari@who.int         

About WHO

The World Health Organization provides global leadership in public health within the United Nations system. Founded in 1948, WHO works with 194 Member States, across six regions and from more than 150 offices, to promote health, keep the world safe and serve the vulnerable. Our goal for 2019-2023 is to ensure that a billion more people have universal health coverage, to protect a billion more people from health emergencies, and provide a further billion people with better health and wellbeing.
 
For updates on COVID-19 and public health advice to protect yourself from coronavirus, visit www.who.int and follow WHO on Twitter, Facebook, Instagram, LinkedIn, TikTok, Pinterest, Snapchat, YouTube